<DOC>
	<DOC>NCT01628549</DOC>
	<brief_summary>To evaluate the safety and effectiveness of 3 strengths of P005672 compared to placebo for the treatment of moderate to severe facial acne.</brief_summary>
	<brief_title>Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of P005672 in Treatment of Facial Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>male or female, 1245 years of age with body weight between 52 and 88 kg diagnosis of acne vulgaris with: 20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open &amp; closed comedones) no more than 2 nodules on the face Investigator's Global Assessment (IGA) score of moderate (3) to severe (4) dermatological condition of face or facial hair that could interfere with clinical evaluations prolonged QTcF(&gt;450msec) on Baseline ECG pseudomembranous colitis or antibioticassociated colitis hepatitis, liver damage or renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>acne</keyword>
</DOC>